A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies

The silver(I) N‐heterocyclic carbene (NHC) complex bis(1‐(anthracen‐9‐ylmethyl)‐3‐ethylimidazol‐2‐ylidene) silver chloride ([Ag(EIA)2]Cl), bearing two anthracenyl fluorescent probes, has been synthesized and characterized. [Ag(EIA)2]Cl is stable in organic solvents and under physiological conditions, and shows potent cytotoxic effects in vitro toward human SH‐SY5Y neuroblastoma cells. The interactions of [Ag(EIA)2]Cl with a few model biological targets have been studied as well as its ability to be internalized in cells. The in vitro anticancer activity is apparently related to the level of drug internalization. Notably, [Ag(EIA)2]Cl does not react with a few model proteins, but is capable of binding the C‐terminal dodecapeptide of thioredoxin reductase hTrxR(488–499) and to strongly inhibit the activity of this enzyme. Binding occurs through an unconventional process leading to covalent binding of one or two carbene ligands to the C‐terminal dodecapeptide with concomitant release of the silver cation. To the best of our knowledge, this mode of interaction is reported here for the first time for Ag(NHC)2 complexes.

[1]  K. Chandy,et al.  The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells , 2017, British Journal of Cancer.

[2]  A. Merlino,et al.  Protein metalation by metal-based drugs: X-ray crystallography and mass spectrometry studies. , 2017, Chemical communications.

[3]  A. Arcangeli,et al.  Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. , 2017, ACS medicinal chemistry letters.

[4]  A. Merlino,et al.  Protein Metalation by Anticancer Metallodrugs: A Joint ESI MS and XRD Investigative Strategy. , 2017, Chemistry.

[5]  L. Messori,et al.  Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments. , 2017, Talanta.

[6]  M. Banchini,et al.  Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes. , 2016, Journal of inorganic biochemistry.

[7]  L. Messori,et al.  Iridium(I) Compounds as Prospective Anticancer Agents: Solution Chemistry, Antiproliferative Profiles and Protein Interactions for a Series of Iridium(I) N-Heterocyclic Carbene Complexes. , 2016, Chemistry.

[8]  S. Lippard,et al.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. , 2016, Chemical reviews.

[9]  L. Messori,et al.  Gold(III) complexes with hydroxyquinoline, aminoquinoline and quinoline ligands: Synthesis, cytotoxicity, DNA and protein binding studies. , 2015, Journal of inorganic biochemistry.

[10]  V. Brabec,et al.  cis-Pt I2(NH3)2: a reappraisal. , 2015, Dalton transactions.

[11]  A. Fernandes,et al.  Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents , 2015, Molecules.

[12]  Q. Ye,et al.  A New Approach to Reduce Toxicities and to Improve Bioavailabilities of Platinum-Containing Anti-Cancer Nanodrugs , 2015, Scientific Reports.

[13]  M. Jakupec,et al.  {Ru(CO)x}-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells , 2014 .

[14]  S. Wölfl,et al.  Gold(I) N‐Heterocyclic Carbene Complexes with Naphthalimide Ligands as Combined Thioredoxin Reductase Inhibitors and DNA Intercalators , 2014, ChemMedChem.

[15]  M. Ginanneschi,et al.  Insights on the mechanism of thioredoxin reductase inhibition by gold N-heterocyclic carbene compounds using the synthetic linear selenocysteine containing C-terminal peptide hTrxR(488-499): an ESI-MS investigation. , 2014, Journal of inorganic biochemistry.

[16]  A. Merlino,et al.  Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. , 2013, Inorganic chemistry.

[17]  A. Casini,et al.  Fluorescent silver(I) and gold(I)-N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights. , 2013, Metallomics : integrated biometal science.

[18]  P. Sadler,et al.  Next-generation metal anticancer complexes: multitargeting via redox modulation. , 2013, Inorganic chemistry.

[19]  R. Rubbiani,et al.  N-Heterocyclic carbene metal complexes in medicinal chemistry. , 2013, Dalton transactions.

[20]  A. Casini,et al.  Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents. , 2012, Journal of medicinal chemistry.

[21]  K. B. Garbutcheon-Singh,et al.  Transition metal based anticancer drugs. , 2011, Current topics in medicinal chemistry.

[22]  M. Ginanneschi,et al.  Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. , 2010, Chemical communications.

[23]  S. Gore,et al.  Arsenic trioxide - An old drug rediscovered. , 2010, Blood reviews.

[24]  C. Cannon,et al.  The medicinal applications of imidazolium carbene-metal complexes. , 2009, Chemical reviews.

[25]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[26]  W. Youngs,et al.  Ag(I) N-heterocyclic carbene complexes: synthesis, structure, and application. , 2005, Chemical reviews.

[27]  Maria Cristina Burla,et al.  SIR97: a new tool for crystal structure determination and refinement , 1999 .

[28]  Abraham Nudelman,et al.  NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities. , 1997, The Journal of organic chemistry.

[29]  S. Lippard,et al.  Understanding and improving platinum anticancer drugs--phenanthriplatin. , 2014, Anticancer research.

[30]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.